WMR SLE patients major contributors in discovery of new mechanisms of lupus related inflammation. 

OP0186 Immune Complex Bound U1 and Y1 RNA Correlates with Interferon-Stimulated Gene Expression and Disease Activity: An Observational Study of Sysytemic Lupus Erythematosus Patients

ArticleinAnnals of the Rheumatic Diseases 75(Suppl 2):127.2-127 · June 2016with2 Reads

DOI: 10.1136/annrheumdis-2016-eular.2747

Abstract

Background Immune complexes (ICs) containing RNA are thought to play a central role in driving interferon (IFN) production and systemic inflammation in systemic lupus erythematosus (SLE) via activation of intracellular Toll-Like Receptors (TLRs). However, quantitation of IC-bound RNAs in SLE patient plasma has not previously been performed. Objectives To quantify IC-associated U1 and Y1 RNA and relate the findings to the interferon (IFN) signature and SLE clinical activity. Methods Medications and SLEDAI measurements were completed on 228 SLE patients > 50 from West Michigan.

Results  Within the U1 RNA-positive groups, the top 10 up-regulated genes were increased 10–48 fold compared to healthy volunteers (associated p values exceeding 10–15) and corresponded to known IFN-inducible transcripts. IC-bound U1 and Y1 RNA levels showed significant correlations with each other and also with disease activity (SLEDAI) (p<0.0003). 

Conclusions The enhanced expression of IFN-inducible transcripts in blood from patients possessing IC-bound U1 and/or Y1 RNA lends further support to the hypothesis that these RNA molecules are involved in triggering TLR7 and stimulating interferon production in SLE patients. Therapeutic strategies that seek to reduce the quantities of RNA associated with ICs may be an attractive approach to blocking downstream IFN production and immune system activation. 

©2015 West Michigan Rheumatology, PLLC                1155 East Paris SE, Suite 100                              Grand Rapids, MI 49546                                               Voice 616.459.8088                                                       FAX 616.459.8312                                                www.mi-arthritis.com